
PhosPrint PhosPrint is pioneering in vivo laser bioprinting for reconstructive surgery. Its flagship system, the InvivoLPrint-U, is the world's first in vivo laser bioprinter designed for the operating room, enabling surgeons to print a patient's own urothelial cells directly onto tissue during neobladder reconstruction. By using the patient's own cells and preserving existing vascularization, the technology eliminates the rejection risk and severe side effects of conventional cystectomy solutions, with preclinical results showing >95% cell viability and restored bladder function. PhosPrint has secured EMA approval for first-in-human trials, holds a growing patent portfolio, and is backed by EU/EIC funding and private investors. Founded and led by pioneers in laser bioprinting, the company is building a platform with applications across a tissue-regeneration market exceeding $20 billion. Technology Developer

PhosPrint

PhosPrint is pioneering in vivo laser bioprinting for reconstructive surgery. Its flagship system, the InvivoLPrint-U, is the world's first in vivo laser bioprinter designed for the operating room, enabling surgeons to print a patient's own urothelial cells directly onto tissue during neobladder reconstruction. By using the patient's own cells and preserving existing vascularization, the technology eliminates the rejection risk and severe side effects of conventional cystectomy solutions, with preclinical results showing >95% cell viability and restored bladder function. PhosPrint has secured EMA approval for first-in-human trials, holds a growing patent portfolio, and is backed by EU/EIC funding and private investors. Founded and led by pioneers in laser bioprinting, the company is building a platform with applications across a tissue-regeneration market exceeding $20 billion.

Technology Developer